{"id":48484,"date":"2022-09-16T14:01:44","date_gmt":"2022-09-16T12:01:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/"},"modified":"2022-09-16T14:01:44","modified_gmt":"2022-09-16T12:01:44","slug":"rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/","title":{"rendered":"Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022"},"content":{"rendered":"
\n

\n\u2014 Updated Data from Phase 1 Danon Disease trial expected to include efficacy and safety data from pediatric cohort and longer-term data from adult cohort \u2014<\/i>\n<\/p>\n

\n\u2014 Company to webcast investor event on Sept. 30, at 8:00 a.m. ET \u2014<\/i>\n<\/p>\n

CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc.<\/a> (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that the Company will present updated clinical data on its Phase 1 Danon Disease Trial for RP-A501 during an oral poster session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 to be held Sept. 30 \u2013 Oct. 3, 2022. On the first day of the meeting at 6:00 a.m., the oral poster presentation will be made available on the congress online portal and the Company will issue a press release. An investor event will subsequently be webcast at 8:00 a.m. Rocket recently announced<\/a> positive initial safety data from two pediatric patients in its Phase 1 Danon Disease trial at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).\n<\/p>\n

<\/a><\/p>\n

\nHFSA Presentation Details<\/b>\n<\/p>\n

\nTitle:<\/b> Safety Profile of the First Pediatric Cardiomyopathy Gene Therapy Trial: RP-A501 (AAV9:LAMP2B) for Danon Disease
\n
Session:<\/b> Inherited Cardiomyopathies, Amyloidosis, Myocarditis, CardioOncology
\n
Presenter:<\/b> Joseph Rossano, M.D., M.S., FAAP, FACC – Co-Director of the Cardiac Center and Chief of the Division of Cardiology at Children’s Hospital of Philadelphia
\n
Session date and time:<\/b> Saturday, Oct. 1, 12:00 \u2013 1:00 p.m. ET
\n
Location:<\/b> Gaylord National Harbor Convention Center, Washington, D.C.
\n
Poster Number:<\/b> 375\n<\/p>\n

\nInvestor Webcast Information<\/b>\n<\/p>\n

\nCompany management will discuss the Danon Disease data via webcast on Sept. 30, 2022, at 8:00 a.m. ET. To access the webcast, please register online at: https:\/\/ir.rocketpharma.com\/events-presentations<\/a>. Participants are requested to register a minimum of 15 minutes before the start of the call.\n<\/p>\n

\nA simultaneous webcast of the presentation will be available under \u201cEvents\u201d in the Investors section of the Company\u2019s website at: https:\/\/ir.rocketpharma.com\/<\/a>. The webcast replay will be available on the Rocket website upon completion of the event.\n<\/p>\n

\nAbout Rocket Pharmaceuticals, Inc.
\n
<\/b>Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company\u2019s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket’s clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rocket\u2019s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com<\/a>.\n<\/p>\n

\nRocket Cautionary Statement Regarding Forward-Looking Statements
\n
<\/b>Various statements in this release concerning Rocket\u2019s future expectations, plans and prospects, including without limitation, Rocket\u2019s expectations regarding its guidance for 2022 in light of COVID-19, the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), and Danon Disease, the expected timing and data readouts of Rocket\u2019s ongoing and planned clinical trials, the expected timing and outcome of Rocket\u2019s regulatory interactions and planned submissions, Rocket\u2019s plans for the advancement of its Danon Disease program and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “will give,” “estimate,” “seek,” “will,” “may,” “suggest” or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket\u2019s ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket\u2019s ongoing trials, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket\u2019s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in Rocket\u2019s Annual Report on Form 10-K for the year ended December 31, 2021, filed February 28, 2022 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/b>
Kevin Giordano
\n
Director, Corporate Communications
\n
kgiordano@rocketpharma.com<\/a>\n<\/p>\n

\nInvestors<\/b>
Jessie Yeung, M.B.A.
\n
Vice President, Investor Relations and Corporate Finance
\n
investors@rocketpharma.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2014 Updated Data from Phase 1 Danon Disease trial expected to include efficacy and safety data from pediatric cohort and longer-term data from adult cohort \u2014 \u2014 Company to webcast investor event on Sept. 30, at 8:00 a.m. ET \u2014 CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48484","6":"format-standard","7":"category-industry"},"yoast_head":"\nRocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u2014 Updated Data from Phase 1 Danon Disease trial expected to include efficacy and safety data from pediatric cohort and longer-term data from adult cohort \u2014 \u2014 Company to webcast investor event on Sept. 30, at 8:00 a.m. ET \u2014 CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-16T12:01:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220916005090\/en\/1151092\/21\/Rocket_Pharma.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022\",\"datePublished\":\"2022-09-16T12:01:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\\\/\"},\"wordCount\":987,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220916005090\\\/en\\\/1151092\\\/21\\\/Rocket_Pharma.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\\\/\",\"name\":\"Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220916005090\\\/en\\\/1151092\\\/21\\\/Rocket_Pharma.jpg\",\"datePublished\":\"2022-09-16T12:01:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220916005090\\\/en\\\/1151092\\\/21\\\/Rocket_Pharma.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220916005090\\\/en\\\/1151092\\\/21\\\/Rocket_Pharma.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/","og_locale":"en_US","og_type":"article","og_title":"Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 - Pharma Trend","og_description":"\u2014 Updated Data from Phase 1 Danon Disease trial expected to include efficacy and safety data from pediatric cohort and longer-term data from adult cohort \u2014 \u2014 Company to webcast investor event on Sept. 30, at 8:00 a.m. ET \u2014 CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-16T12:01:44+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220916005090\/en\/1151092\/21\/Rocket_Pharma.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022","datePublished":"2022-09-16T12:01:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/"},"wordCount":987,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220916005090\/en\/1151092\/21\/Rocket_Pharma.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/","url":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/","name":"Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220916005090\/en\/1151092\/21\/Rocket_Pharma.jpg","datePublished":"2022-09-16T12:01:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220916005090\/en\/1151092\/21\/Rocket_Pharma.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220916005090\/en\/1151092\/21\/Rocket_Pharma.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-present-updated-data-from-phase-1-danon-disease-trial-for-rp-a501-at-the-heart-failure-society-of-america-hfsa-annual-scientific-meeting-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48484"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48484\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}